Acute Ischemic Stroke (AIS) Market is Anticipated to Witness High Growth Owing to Increasing Geriatric Population

Acute Ischemic Stroke (AIS) Market

Acute ischemic stroke (AIS) refers to a medical condition where blood supply gets disrupted to a part of the brain, thereby blocking delivery of oxygen and nutrients to brain tissues. Common symptoms associated with AIS include sudden numbness or weakness, especially on one side of the body, confusion, trouble speaking or understanding speech, difficulty seeing with one or both eyes, trouble walking, dizziness or loss of balance or coordination. The condition is often triggered due to various causes such as formation of blood clots, plaque buildup in arteries leading to blockage, or rupture of blood vessels in the brain. Rising prevalence of cardiovascular diseases, growing cases of strokes among young adults, surging geriatric population worldwide which is highly susceptible to AIS, and favorable reimbursement policies are some key factors driving demand for treatment of AIS.

 The Global Acute Ischemic Stroke (AIS) Market is estimated to be valued at US$ 10612.22 Bn in 2024 and is expected to exhibit a CAGR of 18.% over the forecast period 2024 To 2031.

Key Takeaways

Key players operating in the Acute Ischemic Stroke (AIS) Market are F. Hoffmann-La Roche AG, Boehringer Ingelheim, Bayer AG, Pfizer Inc., Biogen, Daiichi Sankyo, Bristol-Myers Squibb, Johnson & Johnson, AstraZeneca, SanBio and Athersys Inc. Majority of these players are involved in development and launch of innovative drugs and therapies for treatment of acute ischemic stroke. Some notable drugs available in market include tissue plasminogen activator (tPA), antiplatelet drugs, Anticoagulants, Neuroprotective drugs etc.

The key opportunities in the Acute Ischemic Stroke (Ais) Market include increase in acquisitions and collaborations between pharmaceutical companies and biotech startups, growing focus on development of biosimilars and generic drugs, and emergence of novel drug delivery mechanisms such as intra-arterial thrombolysis. Further, governments across various regions are undertaking initiatives and awareness programs to educate people about early symptoms of stroke and benefits of emergency care in improving functional outcomes.

Major players in the AIS market are emphasizing on global expansion through geographical extensions and strategic partnerships. For instance, F. Hoffmann-La Roche AG provides stroke care solutions across developed markets of North America and Europe as well as emerging economies of Asia Pacific and Latin America. Similarly, Johnson & Johnson and Bristol-Myers Squibb have increased their international footprint for commercialization of products indicated for AIS treatment.

Market Drivers

Surging Geriatric Population

The global geriatric population, defined as people aged 65 years or older, is growing exponentially. As per WHO, there were around 703 million people aged 65 years or above globally in 2019 which is projected to reach 1.5 billion by 2050. Older individuals are at higher risk of developing atherosclerosis, high blood pressure and diabetes - key risk factors of AIS. Moreover, aging reduces efficacy of the brain's circulatory system making elderly susceptible to reduced blood flow and blockages. Thus, rising pool of elderly population worldwide is a major driver of acute ischemic stroke market growth.

Market Restraints

Stringent Regulatory Framework

Pharmaceutical regulations for approval of new drug entities and therapies for treatment of AIS are quite stringent given associated risks. Drugs recommended for use within narrow therapeutic window post ischemic stroke event require extensive clinical evaluation. Further, regulatory requirements for biosimilarity and evaluation of long term patient outcomes add to testing timelines and costs. This poses a major challenge for small companies and startups to commercialize innovative therapies within short time thus restraining market potential to a certain extent.

Segment Analysis

The acute ischemic stroke market can be segmented based on drug type, distribution channel, route of administration, and end use. Among drug type, tissue plasminogen activator holds the dominating position as it is the only approved therapy for AIS by FDA and recommended as the standard of care treatment by guidelines. It is administered intravenously within 3 to 4.5 hours of stroke onset to break down blood clots and restore blood flow to the brain.

Global Analysis

Regionally, North America dominates the global AIS market and is expected to continue its dominance during the forecast period. Higher healthcare spending, growing geriatric population, presence of key players, and well-established healthcare infrastructure drive the North American market. However, Asia Pacific region is projected to grow at the fastest CAGR during the forecast period owing to rising public awareness about stroke, expanding private healthcare sector, and increasing healthcare spending in emerging Asian countries like China and India.

Get more insights on – Acute Ischemic Stroke (Ais) Market

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)